Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 200 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 300 Min/Week Clear all
Completed Not applicable Interventional Results available

Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS

NCT02606604
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RT 300: Lower Extremity Cycling
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

NCT04834778
View directory record Official record
Conditions
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
Interventions
HC-5404-FU
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

NAD+ and Exercise in FA

NCT04192136
View directory record Official record
Conditions
Friedreich Ataxia 1
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparing Self-paced Versus Moderate Intensity Physical Activity Recommendation for Midlife Adults

NCT05285748
View directory record Official record
Conditions
Physical Inactivity
Interventions
Self-Paced Intensity Physical Activity, Prescribed Moderate Intensity Physical Activity
Behavioral
Lead sponsor
Brown University
Other
Eligibility
50 Years to 64 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib followed by treatment-free
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

NCT00536978
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
ARA-C, BCNU, Campath-1H, Cyclophosphamide, Etoposide, Fludarabine, Melphalan, Rituximab, Allogeneic Stem Cell Transplantation, Total body radiation (TBI), Methotrexate, Tacrolimus, Adback NK or T Cell
Drug · Other · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke

NCT02465034
View directory record Official record
Conditions
Cerebrovascular Stroke
Interventions
Transcranial Magnetic Stimulation, Traditional Paired Associative Stimulation, Median Nerve Stimulation, Corticocortical Paired Associative Stimulation, Sham Paired Associative Stimulation
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of Therapy Integrating Peer-sharing, Technology, Aerobic and Resistance Training (TIPSTART)

NCT04813198
View directory record Official record
Conditions
Group Meetings
Interventions
TIPSTART
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 34 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut-Brain Neural Coupling in Spinal Cord Injury

NCT07052344
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
Preload condition, Ad-libitum control condition
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

NCT04711824
View directory record Official record
Conditions
Breast Cancer, Brain Metastases, Adult
Interventions
Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy
Drug · Radiation
Lead sponsor
Colette Shen
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
sunvozertinib, Pemetrexed+carboplatin
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Glendale, California • Vallejo, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

NCT00869258
View directory record Official record
Conditions
Pancreatic Cancer Stage IVA
Interventions
Gemcitabine, docetaxel, and capecitabine, Radiation therapy with gemzar
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 11, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 4 Interventional

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

NCT01271218
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diet, Exercise
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

NCT01570686
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
43
States / cities
Los Angeles, California • Riverside, California • Santa Monica, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

NCT01553019
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton radiation, Gemcitabine
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615
View directory record Official record
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Oxidative Stress in Chronic Kidney Disease: Diet and Exercise

NCT01150851
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
caloric restriction, aerobic exercise
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Springfield, Massachusetts • Nashville, Tennessee • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Natalizumab High Titer Immunogenicity and Safety

NCT00516893
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00002-E (natalizumab high titer)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 11, 2026, 5:14 PM EDT